AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
iSpecimen Inc.
Video analysis: ISPC
All videosNo video analysis for this stock yet. Request one from our team.
News: ISPC
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline.
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company's common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923 shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.
E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025 Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025
E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F.
Similar companies
-
ENDRA Life Sciences Inc.
NDRA
·
NASDAQ
Compare
-
Theriva Biologics, Inc.
TOVX
·
New York Stock Exchange Arca
Compare
-
Catheter Precision, Inc.
VTAK
·
New York Stock Exchange Arca
Compare
-
HeartSciences Inc.
HSCS
·
NASDAQ
Compare
-
Galmed Pharmaceuticals Ltd.
GLMD
·
NASDAQ
Compare
-
Bluejay Diagnostics, Inc.
BJDX
·
NASDAQ
Compare